Reported 1 day ago
Novo Nordisk and Eli Lilly, key players in the diabetes and weight-loss drug markets, are facing increased competition as regulators in several countries approve cheaper licensed copies of their patented medications. Drugs like Ozempic and Mounjaro, which have seen soaring sales, may soon confront declining prices due to the influx of these generics, potentially impacting revenue as they rush to meet surging demand for obesity treatments. While the immediate market remains robust, experts anticipate long-term price pressures due to growing competition in developing markets.
Source: YAHOO